Clearmind Medicine (CMND) Stock Price, News & Analysis

Company Overview

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Key Stats

• Today's Range: $1.30 to $1.37
• 50-Day Range: $1.20 to $1.76
• 52-Week Range: $0.92 to $6.80
• Volume: 34,994 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $2.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Clearmind Medicine Stock Analysis - MarketRank™

Clearmind Medicine scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Clearmind Medicine.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Clearmind Medicine has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.52% of the float of Clearmind Medicine has been sold short.

Short Interest Ratio / Days to Cover

Clearmind Medicine has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearmind Medicine has recently increased by 45.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clearmind Medicine does not currently pay a dividend.

Dividend Growth

Clearmind Medicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.52% of the float of Clearmind Medicine has been sold short.

Short Interest Ratio / Days to Cover

Clearmind Medicine has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearmind Medicine has recently increased by 45.63%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Clearmind Medicine this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Clearmind Medicine insiders have not sold or bought any company stock.

Percentage Held by Institutions

96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMND Stock Analysis - Frequently Asked Questions

How have CMND shares performed this year?

Clearmind Medicine's stock was trading at $2.81 at the beginning of 2024. Since then, CMND shares have decreased by 52.3% and is now trading at $1.34.
View the best growth stocks for 2024 here.

How were Clearmind Medicine's earnings last quarter?

Clearmind Medicine Inc. (NASDAQ:CMND) announced its quarterly earnings results on Monday, September, 16th. The company reported ($0.59) earnings per share for the quarter.

When did Clearmind Medicine's stock split?

Clearmind Medicine's stock reverse split on the morning of Tuesday, November 28th 2023. The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Clearmind Medicine IPO?

Clearmind Medicine (CMND) raised $9 million in an IPO on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. served as the underwriter for the IPO.

How do I buy shares of Clearmind Medicine?

Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Clearmind Medicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 9/16/2024
• Today: 11/21/2024
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMND
• CUSIP: N/A
• CIK: 1892500
• Web: www.clearmindmedicine.com
• Phone: 604-260-1566
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,620,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.73%
• Return on Assets: -102.10%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 1.71
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.22 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 1,690,000
• Free Float: N/A
• Market Cap: $2.30 million
• Optionable: Not Optionable
• Beta: 1.26